Introduction
Loss of function of p53 and Msh2 has been shown to impair the normal apoptotic response (Clarke et al., 1993; Lowe et al., 1993b; Toft et al., 1999) . However, outside of haematological systems, loss of gene dependent apoptosis does not appear to correlate with increased survival (Griffiths et al., 1997; Schmitt et al., 2000; Brown and Wouters, 1999; Hendry et al., 1997; Sansom and Clarke, 2000) . Given the aim to tailor chemotherapy to the genetic profile of the tumour (Vogelstein et al., 2000) it is of utmost importance that we truly understand the links between apoptosis and long term cellular survival. Clearly we are not yet in this position; as perhaps best exemplified by the debate that still continues over whether P53 status is a good prognostic indicator of therapeutic outcome in colorectal cancer (Bosari and Viale, 1995) . To further address the fundamental relationship between apoptosis and prolonged survival, we have used murine models to investigate in vivo the impact of loss of the apoptotic response upon long term crypt clonogenic survival as measured by the microcolony assay. We have investigated these endpoints following exposure to three different cytotoxic agents: cisplatin, nitrogen mustard and N-Methyl-N-Nitrosourea (NMNU).
Cisplatin
Cisplatin is a particularly effective chemotherapeutic against testicular and ovarian cancer. In ovarian cancer, resistance to cisplatin has been correlated with loss of the mismatch repair gene MLH1 through promoter hypermethylation (Strathdee et al., 1999) . The putative cytotoxic lesion produced by cisplatin is a GG intrastrand crosslink which both Msh2 and p53 have been shown to bind (Duckett et al., 1996; Kasparkova et al., 2001) . We have previously analysed the response to cisplatin in vivo in the murine intestinal epithelium. In this context, p53 deficiency causes complete abrogation of the immediate wave of apoptosis directly predicting an increase in clonogenic survival. Similar analysis showed Msh2 7/7 deficiency to weakly reduce the apoptotic response, predicting a more modest increase in survival.
We characterized the apoptotic response to cisplatin at 10 mg/kg, 15 mg/kg and 20 mg/kg of cisplatin at 6 h following exposure (Figure 1a) . A dose dependent increase in apoptosis was seen in wild type intestinal enterocytes in response to cisplatin. Msh2 deficiency caused a slight yet significant reduction in the apoptotic response and again there was a drug dose dependent increase. P53 deficiency caused a complete abrogation of the apoptotic response at all three doses.
In order to investigate whether there was a delayed apoptotic response in the p53 7/7 and (Msh2 7/7 , p53 7/ 7 ) mice, the apoptotic response was scored over a 72 h period following cisplatin treatment. As has been reported with g-irradiation Merritt et al., 1997) and temozolomide (Toft et al., 1999) there was a delayed wave of p53 independent apoptosis which peaked at 24 h following cisplatin treatment. Previous reports by Gong et al. (1999) argued that functional mismatch repair (MMR) was required to upregulate P73 and so mediate apoptosis in the absence of p53 following cisplatin treatment. However after cisplatin treatment there is a delayed wave of apoptosis in the (Msh2 7/7 , p53 7/7 ) mice indistinguishable from p53 7/7 mice ( Figure 1b ). This raises two possibilities; first, that p73 is still induced in the (Msh2
, p53 7/7 ) mice independently of MMR; or second, that p73 is not necessary for this delayed wave of apoptosis.
To determine the effect of p53 and Msh2 deficiency on micro-colony survival, mice mutant for both genes were exposed to 15 mg/kg of cisplatin (10 mg/kg of cisplatin does not result in detectable crypt killing). Both p53 7/7 and (Msh2 7/7 , p53 7/7 ) mice showed an increase in survival compared to wild type mice ( Figure  1c) . At the higher dose of 20 mg/kg the extent of killing by cisplatin was increased with nearly total crypt death in the wild type and Msh2 7/7 mice. P53 deficiency led to a marked increase in survival (Figure 1d ).
We therefore demonstrate increased crypt survival following loss of p53-dependent apoptosis. This is the first time such an in vivo correlation has been reported. Our data is supported by the studies of Branch et al. (2000) in ovarian cell lines where P53 is a major component of cisplatin resistance. These results predict that cisplatin would kill most effectively in a P53 +/+ environment. In the light of this finding it is interesting that testicular cancers are very sensitive to cisplatin treatment and very rarely show P53 mutations (Fleischhacker et al., 1994; Lutzker and Levine, 1996) . Indeed testicular cancers have been shown to display very high levels of wild type P53 following chemotherapy and the rare cases of resistance to cisplatin have been associated with loss of P53 (Houldsworth et al., 1998) .
Nitrogen mustard
Nitrogen mustard is one of the oldest chemotherapeutics still in clinical use (Hemminiki, 1994) . It produces crosslinks in the DNA and is a potent Figure 1 (a) Apoptosis was scored as previously described (Toft et al., 1999) in 8 -12 week old mice 6 h following i.p. injection of 10, 15 and 20 mg/kg of cisplatin (Faulding pharmaceuticals). Msh2 and p53 mutant animals were derived from an outbred colony segregating for Ola/129, Balb c and SWR genomes. Black bars, wild type mice; open bars, Msh2 7/7 mice, grey bars, p53 7/7 mice. At least three mice were used for every time point and error bars represent s.d. Counts represent the number of apoptotic bodies in 50 half crypts. Deficiency of p53 led to loss of the apoptotic response at 6 h at all doses compared to wild type mice (Mann -Whitney, P=0.04) whilst Msh2 deficiency caused a significant reduction in apoptosis at all doses used (Mann -Whitney, P=0.04). (b) Apoptosis scored over a 72 h timecourse following 15 mg/kg of cisplatin. In both p53 7/7 and (Msh2
) mice there is a delayed wave of p53 independent apoptosis. (c) Clonogenic survival at 15 mg/kg of cisplatin.
Both p53
7/7 and (Msh2 7/7 , p53 7/7 ) mice showed increased clonogenic survival compared to wild type and Msh2 7/7 mice (Mann -Whitney, P=50.04). The micro-colony assay was performed as described by Potten (1990) and Hendry et al. (1997) . Briefly, 72 h after injection with cytotoxic agents, murine small intestines were removed, cut into small pieces and bound into a bundle with 3M surgical tape. These were fixed in 10% formalin and embedded. Histological cross sections were made and the numbers of surviving crypts were counted around the circumference of the intestine. A minimum of 10 circumferences (as defined by analysis of the running mean) were counted per mouse from the proximal 15 cm of the small intestine. As all mice were killed at the same time and comparisons between genotypes were being made, there was no rationale for applying any correction factor (Potten and Hendry, 1985) . (d) Microcolony survival at 20 mg/ kg of cisplatin. Again p53 7/7 mice showed increased clonogenic survival compared to wild type and Msh2 7/7 mice (Mann -Whitney, P=50.04) inducer of apoptosis, implicating a p53 dependent apoptotic response in the small intestine. We scored apoptosis in wild type, Msh2 7/7 and p53 7/7 mice 6 h after exposure to Nitrogen Mustard. At the levels of Nitrogen mustard used, no drug dose dependency was observed in the apoptotic response (Figure 2a) . A small, significant reduction in apoptosis was seen in Msh2 7/7 mice at 1 mg/kg and 5 mg/kg (P=0.04 Mann -Whitney U test). No induction of apoptosis above basal levels was observed in the p53 7/7 mice. To investigate whether there was a delayed apoptotic response in the p53 7/7 mice, the apoptotic response was scored over a 72 h period following Nitrogen Mustard treatment (Figure 2b) . A small delayed wave of p53 independent apoptosis was observed, which was highest 24 h following treatment. We next addressed the effect of gene status upon clonogenic survival. Figure 2c shows survival as determined by the micro-colony assay following 1, 5 and 10 mg/kg Nitrogen Mustard. Despite the clear gene dependency of the apoptotic response no gene dependency was observed in crypt survival for either Msh2 7/7 or p53 7/7 mice.
N-methyl-N-Nitrosourea (NMNU)
The alkylating agents MNNG, NMNU and temozolomide are thought to induce apoptosis through the production of the cytotoxic O-6 methyl guanine (O6meG) lesion (Karran and Bignami, 1994) . Duckett et al. (1996) have shown that Msh2-Msh6 complex (MutS alpha) can bind this lesion. The alkylating agents temozolomide and MNNG have been shown to induce MMR dependent apoptosis in the murine intestine (Toft et al., 1999) . Thus far all studies have shown that there is increased survival in MMR deficient cell lines following methylating agents MNNG, temozolomide and NMNU. The role of p53 is much more debatable with diverse results reported from different systems (Toft et al., 1999; Duckett et al., 1999; Hickman and Samson, 1999; Ochs and Kaina, 2000) . Apoptosis was scored 6 h following NMNU treatment. As with cisplatin, a drug dose dependent response was observed in both wild type and Msh2 7/ 7 mice (Figure 3a) . Msh2 7/7 mice showed a significant reduction in the level of apoptosis at each dose. Loss of p53 causes abrogation of the apoptotic response at 6 h. At 72 h, the apoptotic response was greatly reduced (Figure 3b) , although it was significantly higher than at 6 h (P=0.02 Mann -Whitney), indicating a wave of p53-independent apoptosis.
Previously, NMNU has not been characterised with respect to crypt survival using the micro-colony assay. We therefore used an escalating dose of NMNU in order to determine its impact upon crypt survival (Figure 3c) . A dose of 150 mg/kg of NMNU results in a high level of crypt death in wild type mice. In the absence of Msh2 there was an increase in survival at this dose, but this was not observed in the absence of p53. For a summary of all apoptotic and crypt survival data see Table 1 . 7/7 mice; grey bars, p53 7/7 mice. At least three mice were used for every time point and error bars represent s.d. Deficiency of p53 led to loss of the apoptotic response at 6 h at all doses (Mann -Whitney, P=0.04) compared to wild type mice whilst Msh2 deficiency caused a small yet significant reduction at 1 and 5 mg/kg (Mann -Whitney, P=0.04) though not 10 mg/kg (Mann -Whitney, P=0.2). (b) Apoptosis scored over a 72 h timecourse following 5 mg/kg of Nitrogen Mustard. In the p53 7/7 mice there is a delayed wave of p53 independent apoptosis peaking at 24 h. (c) Microcolony survival at 1, 5 and 10 mg/kg of Nitrogen Mustard. There were no significant differences in clonogenic survival for any of the three genotypes (Mann -Whitney, P40.10)
Drug specific differences in the gene-dependent damage response
Msh2 deficiency led to a reduction in the apoptotic response to cisplatin and nitrogen mustard. In the case of nitrogen mustard, this reduction in apoptosis is unexpected as there is no existing evidence that MMR recognises this type of damage. This could reflect a compromised generic apoptotic response in the MMR deficient mice, consistent with studies that have shown MMR to be important after a wide range of DNA damage (DeWeese et al., 1998; Fink et al., 1998) . Another explanation for the reduction of apoptosis in Msh2 7/7 mice is that p53 upregulation and phosphorylation is partially dependent on functional MMR (as has been shown for both cisplatin and MNNG (Toft et al., 1999; Lin et al., 2001) ), such that absence of MMR could lead to a reduction in the p53 dependent wave of apoptosis.
Similar results were obtained following NMNU treatment of Msh2 7/7 mice, where there was also a reduced apoptotic response and increased clonogenic survival. This is consistent with previous data where loss of mismatch repair caused increased survival in vitro in ES cells following temozolomide and increased mutational burden in vivo following temolozomide, MNNG and NMNU (Andrew et al., 1998; Toft et al., 1999; Sansom et al., 2001) . This data therefore supports the paradigm of failed apoptosis leading to an increase in survival and therefore a higher burden of mutation burden. Therefore we have shown that loss of p53 or Msh2 can confer resistance in vivo. In the case of cisplatin, this would directly predict that p53 status would be critical to therapy.
Despite the existence of correlations between apoptosis and crypt survival, this was only observed in two out of six experiments performed here. For example, Msh2 deficiency did not lead to increased survival following either Nitrogen Mustard or cisplatin, despite a small reduction in the apoptotic response. Previous reports have strongly associated loss of MMR with cisplatin resistance in ovarian tumors. One explanation for our failure to observe increased survival may be that we used saturating levels of DNA damage, which obscured the impact of MMR deficiency. We believe this is unlikely as we have previously shown that Msh2 deficiency does not cause Figure 3 (a) Apoptosis scored at 6 h following 50, 100 and 150 mg/kg of NMNU. At least three mice were used for every time point and error bars represent s.d. P53 deficiency led to loss of the apoptotic response at 6 h at all doses (Mann -Whitney, P50.04) compared to wild types whilst Msh2 deficiency caused a significant reduction at all doses (Mann -Whitney, P50.04). (b) Apoptosis scored at 6 and 72 h following 150 mg/kg NMNU treatment. In the p53 7/7 mice there is a significant increase in apoptosis at 72 h (Mann -Whitney, P=0.02), corresponding to a delayed wave of p53 independent apoptosis. (c) Clonogenic survival at 50, 100 and 150 mg/kg of NMNU. Doses of 50 and 100 mg/kg do not produce high levels of crypt killing. 150 mg/ kg kills approximately 50% of crypts in wild type and p53 7/7 mice. Msh2 deficiency causes a significant increase in crypt survival (Mann -Whitney, P=0.02) For apoptosis: single row pointing up, normal apoptotic response; single arrow pointing down, slight (though significant) reduction; two arrows down, large reduction in the apoptotic response, three arrows, virtually no apoptotic response. For clonogenic data: one arrow pointing down, normal survival, one arrow pointing up, increased survival increases in mutation following low levels of cisplatin exposure ). Furthermore we show that the apoptotic response was not saturated at 15 mg/kg, the dosage used for the micro-colony assay. The studies reported here have been performed in normal intestinal enterocytes. It remains possible that the reliance upon functional MMR markedly differs between normal and neoplastic cells. Pertinently, Strathdee et al. (2001) have shown that mouse embryonic fibroblasts deficient for Msh2 still undergo a G2 arrest following cisplatin treatment in marked contrast to MMR deficient tumour cell lines which lose this checkpoint (Brown et al., 1997) . In fact, clonogenic survival appears to be very cell line and context dependent, as Lin et al. (2001) showed that P53 does not affect survival in colorectal cell lines following cisplatin treatment in contrast to the study here and that by Branch et al. (2000) . Probably the best study highlighting the importance of cellular context for apoptosis and clonogenic survival was performed by Schmitt et al. (2000) . Here, using primary lymphomas, apoptosis and Bcl-2 status were shown to be important for multidrug resistance and long term survival, however following culture in vitro, Bcl-2 status was no longer important for clonogenic survival.
Our results reiterate the role of p53 as a central mediator of the apoptotic response to DNA damaging agents in the murine small intestine (Clarke et al., 1994) ; however deficiency for p53 did not lead to increased crypt survival following either Nitrogen Mustard or NMNU. Thus it is clear that not all those cells that escape the immediate wave of apoptosis can survive long-term. This may help explain the apparent confusion over the role of p53 following alkylating agents, as although p53 is important for the immediate wave of apoptosis this does not translate into long term survival. Thus in terms of final outcome (survival) our results concur with those of Hickman and Samson (1999) , despite their failure to observe P53 dependent apoptosis.
Our findings also concur with previous studies of the effect of p53 deficiency following g-irradiation, where there was no increase in crypt survival; and after 5-FU damage, where increased survival was independent of apoptosis (Pritchard et al., 1998) . Overall (including the three agents used here) loss of p53 dependent apoptosis can only potentially explain increased clonogenic survival in one out of the five agents used in vivo (Hendry et al., 1997) .
One remaining question relates to the fate of those cells that do not engage apoptosis but do not survive over the long term. Four possibilities arise: The first is delayed apoptosis. We show that this does occur, but at greatly reduced levels compared to the immediate (6 h) apoptotic response and outwith the time frame that would impact upon clonogenic survival as scored by the microcolony assay. Delayed apoptosis may therefore affect survival at later times, but it cannot be used to explain the death of crypts at 72 h. The second possibility is permanent arrest or senescence. This mechanism was invoked by Pritchard et al. (1998) to explain the increased survival in the p53 7/7 animals after 5-FU treatment. The principal difficulty with evaluating this is the lack of good markers for stem and clonogenic cells, which makes it impossible to accurately determine which cells enter permanent arrest (Potten, 1990) . The third possibility is necrosis. However no necrosis was observed during these studies. The final possibility is deletion of otherwise viable cells as a consequence of loss of endothelial cells, which has been reported to occur following high levels of g-irradiation (Paris et al., 2001) . Although some of the data presented here supports this mechanism, critically we demonstrate other scenarios where enterocyte apoptosis predicts long term survival, arguing that the importance of endothelial apoptosis is agent type specific.
Whatever the mechanism of the loss of these cells, these studies highlight that our assumptions concerning apoptosis and long term survival need to be readdressed. For example, the simple hypothesis (that loss of apoptosis directly results in increased survival) predicts that 5-FU and irradiation would be ineffective in treating P53 deficient colorectal cancer. However, this clearly cannot be true as g-irradiation and 5-FU remain two of the most clinically effective treatments for colorectal cancer.
Taken together, our findings show that apoptosis cannot be used to directly predict long-term survival. Other studies have shown clonogenic survival can vary from cell line to cell line and from in vitro to in vivo (Brown and Wouters, 1999; Schmitt et al., 2000) . In fact, predicting long term survival on the basis of gene dependent apoptosis in vivo appears to be virtually impossible, highlighting the difficulties in extrapolating system based responses from individual cellular responses. Interpreting these relationships represents a significant challenge for our understanding of systems physiology and has clear implications for any future attempts to predict clinical responsiveness based upon the status of a given death pathway.
